Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Heinrich

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Journal of Medicinal Chemistry|August 11, 2012
3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic Acids: highly potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase AKR1C3Stephen M F Jamieson, Darby G Brooke, Daniel Heinrich, et al.
BMC Cancer|July 25, 2024
A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)Primo N Lara, Luis Villanueva, Carolina Ibanez, et al.
The Lancet. Oncology|May 20, 2014
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trialOliver Sartor, Robert Coleman, Sten Nilsson, et al.
Frontiers in Pharmacology|September 11, 2023
An international comparative analysis and roadmap to sustainable biosimilar marketsKhalid A Alnaqbi, Agnès Bellanger, Alex Brill, et al.
Future Oncology (London, England)|July 12, 2024
Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancerNeeraj Agarwal, Arun A Azad, Joan Carles, et al.
Acta Oncologica (Stockholm, Sweden)|March 27, 2020
Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction studyAnne Hansen Ree, Vigdis Nygaard, Kjetil Boye, et al.
European Urology|July 15, 2017
Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer TrialChristopher C Parker, Robert E Coleman, Oliver Sartor, et al.
The Lancet. Oncology|June 18, 2021
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 studyChung-Han Lee, Amishi Yogesh Shah, Drew Rasco, et al.
ESMO Open|August 2, 2017
Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimateAnne Hansen Ree, Hege G Russnes, Daniel Heinrich, et al.
Journal of Translational Medicine|May 15, 2022
Improving public cancer care by implementing precision medicine in Norway: IMPRESS-NorwayÅslaug Helland, Hege G Russnes, Gro Live Fagereng, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Journal of Medicinal Chemistry|August 11, 2012
3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic Acids: highly potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase AKR1C3Stephen M F Jamieson, Darby G Brooke, Daniel Heinrich, et al.
BMC Cancer|July 25, 2024
A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)Primo N Lara, Luis Villanueva, Carolina Ibanez, et al.
The Lancet. Oncology|May 20, 2014
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trialOliver Sartor, Robert Coleman, Sten Nilsson, et al.
Frontiers in Pharmacology|September 11, 2023
An international comparative analysis and roadmap to sustainable biosimilar marketsKhalid A Alnaqbi, Agnès Bellanger, Alex Brill, et al.
Future Oncology (London, England)|July 12, 2024
Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancerNeeraj Agarwal, Arun A Azad, Joan Carles, et al.
Acta Oncologica (Stockholm, Sweden)|March 27, 2020
Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction studyAnne Hansen Ree, Vigdis Nygaard, Kjetil Boye, et al.
European Urology|July 15, 2017
Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer TrialChristopher C Parker, Robert E Coleman, Oliver Sartor, et al.
The Lancet. Oncology|June 18, 2021
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 studyChung-Han Lee, Amishi Yogesh Shah, Drew Rasco, et al.
ESMO Open|August 2, 2017
Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimateAnne Hansen Ree, Hege G Russnes, Daniel Heinrich, et al.
Journal of Translational Medicine|May 15, 2022
Improving public cancer care by implementing precision medicine in Norway: IMPRESS-NorwayÅslaug Helland, Hege G Russnes, Gro Live Fagereng, et al.
Pageof 6